RIZ1 expression in gliomas and its association with patient prognosis
10.3724/SP.J.1008.2014.00847
- Author:
Chen-Ran ZHANG
1
Author Information
1. Department of Neurosurgery, Changzheng Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Clinical pathology;
Glioma;
Prognosis;
RIZ1
- From:
Academic Journal of Second Military Medical University
2014;35(8):847-851
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression levels of retinoblastoma protein-interacting zinc finger gene 1 (RIZ1) in gliomas of different grades and its association with patient prognosis. Methods The expression of RIZ1 and Ki-67 in 51 glioma tissues of different grades were evaluated immunohistochemically. The correlation of RIZ1 immunoreactivity with the clinicopathological features and the prognostic value of RIZ1 in patients were analyzed. Results Immunohistochemistry results showed that RIZ1 was mainly expressed in the cytoplasm and Ki-67 was mainly located in the nuclei. We found that low grade glioma tissue had a significantly higher expression of RIZ1 compared with the high grade one ([7.55±4.39]% vs [48.83±4.34]%,P<0.000 1). There was a negative correlation between RIZ1 and Ki-67 immunoreactivity (Spearman: r=-0.813 0, P<0.000 1). It was also suggested that RIZ1 expression was negatively associated with tumor grade and patient age (P<0.05). Kaplan-Meier survival analysis revealed a positive correlation between expression of RIZ1 and progress-free survival (PFS) and overall survival (OS) of patients(P<0.000 1). Univariate analysis revealed that high RIZ1 expression and low Ki-67 expression were associated with better patient prognosis. Multivariate analysis using the Cox proportional hazards model revealed that high RIZ1 expression was significantly correlated with prognosis of patients with gliomas(P=0.000,HR=0.164,95%CI:0.071-0.378). Conclusion It is concluded that RIZ1 expression is decreased with the increase of pathological grade of gliomas, and it is associated with patients prognosis; RIZ1 may serve as a marker for treatment and prognosis prediction of gliomas.
